News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
223,093 Results
Type
Article (7233)
Company Profile (18)
Press Release (215842)
Section
Business (63340)
Career Advice (293)
Deals (14800)
Drug Delivery (25)
Drug Development (36974)
Employer Resources (24)
FDA (6455)
Job Trends (4939)
News (122265)
Policy (11709)
Tag
Academia (567)
Alliances (14727)
Alzheimer's disease (545)
Approvals (6435)
Artificial intelligence (51)
Bankruptcy (144)
Best Places to Work (4583)
Breast cancer (46)
Cancer (563)
Cardiovascular disease (42)
Career advice (256)
CAR-T (36)
Cell therapy (113)
Clinical research (30320)
Collaboration (141)
COVID-19 (696)
C-suite (38)
Data (693)
Diabetes (60)
Diagnostics (2156)
Drug pricing (33)
Earnings (32500)
Events (30191)
Executive appointments (104)
FDA (6734)
Funding (121)
Gene therapy (78)
GLP-1 (141)
Government (1258)
Healthcare (6135)
Infectious disease (732)
Inflammatory bowel disease (47)
Interviews (45)
IPO (7924)
Job creations (572)
Job search strategy (220)
Layoffs (38)
Legal (2088)
Liver cancer (35)
Lung cancer (93)
Manufacturing (54)
Medical device (4515)
Medtech (4516)
Mergers & acquisitions (6954)
Metabolic disorders (153)
Neuroscience (649)
NextGen Class of 2024 (1511)
Non-profit (720)
Northern California (726)
Obesity (85)
Opinion (65)
Patents (57)
People (14210)
Phase I (9635)
Phase II (13367)
Phase III (10031)
Pipeline (319)
Postmarket research (799)
Preclinical (3514)
Radiopharmaceuticals (115)
Rare diseases (93)
Real estate (1002)
Regulatory (8879)
Research institute (510)
Resumes & cover letters (39)
Southern California (615)
Startups (678)
United States (6023)
Vaccines (117)
Weight loss (57)
Date
Today (62)
Last 7 days (463)
Last 30 days (1932)
Last 365 days (17165)
2024 (15622)
2023 (19227)
2022 (22380)
2021 (23754)
2020 (21886)
2019 (14526)
2018 (10687)
2017 (11507)
2016 (9619)
2015 (11811)
2014 (8140)
2013 (5899)
2012 (6070)
2011 (6785)
2010 (6257)
Location
Africa (174)
Arizona (34)
Asia (17284)
Australia (4763)
California (1548)
Canada (719)
China (110)
Colorado (57)
Connecticut (80)
Europe (27396)
Florida (209)
Georgia (33)
Illinois (109)
Indiana (76)
Japan (38)
Maryland (207)
Massachusetts (1160)
Minnesota (59)
New Jersey (571)
New York (505)
North Carolina (278)
Northern California (726)
Ohio (41)
Pennsylvania (414)
South America (300)
Southern California (615)
Texas (218)
Utah (34)
Virginia (34)
Washington State (246)
223,093 Results for "exonate limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Exonate Appoints Dr Rafiq Hasan as Non-Executive Director
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director.
May 28, 2024
·
2 min read
Business
Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies
Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8 billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases.
June 18, 2024
·
2 min read
·
Tyler Patchen
Business
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Ascidian Therapeutics today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.
June 18, 2024
·
3 min read
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal announced new findings from a biomarker study in non-small cell lung cancer patients with exon 20 insertion mutations, highlighting sunvozertinib as an effective treatment for this patient population.
May 24, 2024
·
6 min read
Pharm Country
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application (“sNDA”) for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration (NMPA).
March 27, 2024
·
10 min read
Duchenne muscular dystrophy
Dyne Touts ‘Unprecedented’ Dystrophin Expression in Phase I/II DMD Trial for Exon-Skipping Therapy
The highly anticipated results come as the company makes significant changes to its C-suite. Despite the turnover, Dyne said it is looking toward expedited approval pathways for its DMD treatment.
September 3, 2024
·
3 min read
·
Tristan Manalac
Press Releases
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
November 8, 2024
·
5 min read
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Dizal (SSE:688192) announced today that two abstracts featuring the latest data on sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31 through June 4 in Chicago.
April 24, 2024
·
6 min read
Sunvozertinib’s Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal presented the latest data from the inaugural global pivotal study WU-KONG1 Part B of sunvozertinib in relapsed or refractory non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations at the 2024 American Society of Clinical Oncology Annual Meeting.
June 2, 2024
·
7 min read
1 of 22,310
Next